Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL280534 | 0.90 | CA12 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL264780 | 0.76 | CA12 (0.41) | CA12CA1CA2CA9 | |
| SCHEMBL10182407 | 0.75 | CA12 (0.41) | CA12CA1CA2CA9 | |
| SCHEMBL264551 | 0.75 | CA12 (0.39) | CA12CA1CA2CA9 | |
| SCHEMBL264550 | 0.67 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL264919 | 0.67 | CA12 (0.38) | CA12CA1CA2CA9 | |
| SCHEMBL12253922 | 0.67 | CA12 (0.37) | CA12CA1CA2CA9 | |
| SCHEMBL264673 | 0.66 | P2RY1 (0.35) | — | |
| SCHEMBL882101 | 0.64 | CA12 (0.35) | CA12CA1CA2CA9 | |
| SCHEMBL12261176 | 0.63 | CA12 (0.39) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | CA12 4647/4885CA1 4775/4885CA2 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.